Navigation Links
SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
Date:8/5/2009

MUMBAI, India, Aug. 5 /PRNewswire/ -- SIRO Clinpharm, a global, full service Contract Research Organization (CRO) founded in India, today announced the successful completion of the implementation phase of the Oracle Life Science Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial Management System and Oracle Adverse Events Reporting System.

"We are excited to have the rollout of the entire OLSAS as per our plan for the India operations," said Dr. Ajit Nair, President, India Operations, SIRO Clinpharm. "This will help us manage critical tasks in clinical operations and drug safety in an efficient and globally compliant manner, thus providing our clients the best of technology support to run trials more efficiently."

After this implementation, SIRO gains complete operational functionality of the Oracle suite. SIRO, in April, had gone live with the industry standard Oracle Clinical and Oracle RDC, integrated with TMS for its Clinical Data Management Services.

The OLSAS product portfolio for SIRO is comprised of Siebel Clinical Trial Management System 8.0 (CTMS), Adverse Events Reporting System 4.6 (AERS), Oracle Clinical 4.5.3 (OC), Remote Data Capture 4.5.3 (RDC) and Thesaurus Management System 4.6 (TMS).

SIRO plans to roll out the OLSAS to its European operations soon to have the system working in all geographies in which the company has operations.

About SIRO

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the pharmaceutical, biotechnology and medical devices sectors in compliance with international standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Germany, Romania, Estonia and Greece. SIRO has recently opened offices in Czech Republic & Spain.


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
3. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
4. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
5. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
6. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
7. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
8. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the ... dispensaries and head shops –can’t help but be heartened by the industry’s current surge. ... odor aptly described as “skunk smell.” At last they can simply, safely and ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South ... special report in the May issue of Consumer Reports focused on heart health. ... results achieved during and after coronary bypass and aortic valve replacement procedures. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... As part ... Museum today to honor the victims of the Holocaust and Nazi persecution, Center ... at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next ...
(Date:4/24/2017)... ... ... The California Dental Association Foundation’s two-day volunteer dental clinic, CDA Cares ... April 22-23 event at the San Mateo Event Center. , In addition to ... Cares educates the public and policymakers about the importance of good oral health and ...
Breaking Medicine News(10 mins):